TIMI 2A

TIMI IIA compared the results of 3 strategies of coronary angiography and angioplasty following intravenous thrombolytic therapy for ST elevation myocardial infarction: immediate invasive, delayed invasive (18-48 h), and a conservative strategy.

PRESENTATIONS

TIMI 2A Slides

PUBLICATIONS

Update from the Thrombolysis in Myocardial Infarction Trial

Announcement of protocol change in thrombolysis in myocardial infarction trial

The Thrombolysis in Myocardial Infarction (TIMI) phase II pilot study: tissue plasminogen activator followed by percutaneous transluminal coronary angioplasty

Coronary angioplasty after recombinant tissue-type plasminogen activator in acute myocardial infarction: a report from the Thrombolysis in Myocardial Infarction (TIMI) Trial

Immediate vs delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction. TIMI II A results. The TIMI Research Group

Variables predictive of good functional outcome following thrombolytic therapy in the Thrombolysis in Myocardial Infarction phase II (TIMI II) pilot study

The Thrombolysis in Myocardial Infarction (TIMI) Trial phase II: additional information and perspectives

Tissue plasminogen activator followed by percutaneous transluminal coronary angioplasty: one-year TIMI phase II pilot results. TIMI Investigators

Comparison of immediate invasive, delayed invasive, and conservative strategies after tissue-type plasminogen activator. Results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II-A trial

Thrombolysis in Myocardial Infarction (TIMI) Risk Index predicts long-term mortality and heart failure in patients with ST-elevation myocardial infarction in the TIMI 2 clinical trial

 

 

 

 

 

 

%d bloggers like this:
search previous next tag category expand menu location phone mail time cart zoom edit close